Company: SCLXW
Filing Date: 2025-02-27
Form Type: DEF 14A
Source: 0001193125-25-039223
Chunk: 20

Company: Scilex Holding Co
Filing Date: 2025-02-27
Form: DEF 14A
Chunk 20
---
 of $11.50 per share. 12

Pursuant to the Warrant Agreement, dated as of January 6, 2021 (the “Public Warrant Agreement”), between us and Continental Stock Transfer & Trust Company, as warrant agent, the number of shares of Common Stock issuable upon exercise of each Public Warrant shall be decreased in proportion to the decrease in outstanding shares of our Common Stock. Notwithstanding the foregoing, the Public Warrant Agreement provides that the Company may not issue fractional shares upon the exercise of the Public Warrants, and the number of shares to be issued upon such exercise will be adjusted as described in the Public Warrant Agreement. The exercise price for each Public Warrant shall also be adjusted (to the nearest cent) by multiplying such exercise price immediately prior to the Reverse Stock Split by a fraction (x) the numerator of which shall be the number of shares of Common Stock purchasable upon the exercise of the Public Warrants immediately prior the Reverse Stock Split, and (y) the denominator of which shall be the number of shares of Common Stock so purchasable immediately thereafter. The Public Warrants are currently registered under Section 12(b) of the Exchange Act and are quoted on the Nasdaq Capital Market under the symbol “SCLXW.” The Reverse Stock Split would not affect the registration of our Public Warrants under the Exchange Act. Effects of the Reverse Stock Split on All Other Outstanding Warrants.As of the Record Date, in addition to the Public Warrants, the Company has the following outstanding warrants to purchase shares of Common Stock:

| 1. | warrants to purchase up to 6,500,000 shares of Common Stock, held by Oramed Pharmaceuticals Inc., with an 
 exercise price of $0.01 per share (the “Oramed Warrants”);                                                |

| 2. | (a) warrants to purchase up to 3,803,447 shares of Common Stock, issued to the investors pursuant to the                                                                                                          
 Underwriting Agreement, dated February 29, 2024, by and among the Company, Rodman & Renshaw LLC and StockBlock Securities LLC, with an exercise price of $1.70 per share (the “Bought Deal Common Warrants”), and 
 (b) warrants to purchase up to 470,588 shares of Common Stock, issued to StockBlock Securities LLC, with an exercise price of $2.125 per share (the “Bought Deal Representative Warrants”);                       |

|